FMP

FMP

Enter

SQZ - SQZ Biotechnologies ...

Financial Summary of SQZ Biotechnologies Company(SQZ), SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for pat

photo-url-https://financialmodelingprep.com/image-stock/SQZ.png

SQZ Biotechnologies Company

SQZ

NYSE

Inactive Equity

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

0.435 USD

0.165 (37.93%)

About

ceo

Dr. Howard Bernstein M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.sqzbiotech.com

exchange

NYSE

Description

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations wi...

CIK

0001604477

ISIN

US78472W1045

CUSIP

78472W104

Address

200 Arsenal Yards Boulevard

Phone

617 758 8672

Country

US

Employee

53

IPO Date

Oct 30, 2020

Summary

CIK

0001604477

Exchange

NYSE

Industry

Biotechnology

Sector

Healthcare

CUSIP

78472W104

ISIN

US78472W1045

Country

US

Price

0.43

Beta

2.71

Volume Avg.

553.61k

Market Cap

12.83M

Shares

-

52-Week

0.25-3.56

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.2

P/B

-

Website

https://www.sqzbiotech.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest SQZ News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep